As the ABL1 mutation itself was not associated with a worse prognosis of CML-BC and was almost always accompanied by other mutations, targeting other mutations in combination with TKIs may be a promising treatment strategy in the future. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.